Vera Therapeutics (VERA) officer reports 10,000-share sale after option exercise

Q: What insider transaction did Vera Therapeutics (VERA) disclose?

Vera Therapeutics disclosed that its Chief Regulatory Officer exercised a stock option for 10,000 shares of Class A common stock at $15.53 per share and sold 10,000 shares on December 15, 2025 .

Q: At what prices did the Vera Therapeutics (VERA) officer buy and sell shares?

The officer acquired shares through an option exercise at $15.53 per share and sold 10,000 shares at a weighted average price of $50.0767 per share, with individual sale prices ranging from $50.00 to $50.11 .

Q: Was the Vera Therapeutics (VERA) share sale made under a Rule 10b5-1 plan?

Yes. The sale of 10,000 shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2025 .

Q: What type of derivative security did the Vera Therapeutics (VERA) insider exercise?

The insider exercised a stock option (right to buy) for 10,000 underlying shares of Class A common stock at an exercise price of $15.53 per share, with an option expiration date of January 4, 2034 .

Q: What is the vesting schedule for the Vera Therapeutics (VERA) stock option mentioned?

According to the disclosure, 1/4 of the shares subject to the option vested on January 5, 2025 , and 1/48 of the shares vest monthly thereafter, subject to the officer’s continuous service.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Vera Therapeutics’ Chief Regulatory Officer reported an option exercise and share sale. On December 15, 2025, the officer exercised a stock option to buy 10,000 shares of Class A common stock at $15.53 per share, then sold 10,000 shares of Class A common stock in the open market at a weighted average price of $50.0767 per share under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. Following these transactions, the officer directly owned 22,500 shares of Class A common stock and held 245,000 stock options directly.

Insider Trade Summary

Net Seller: 10,000 shares ($500,767)

Net Sell 3 txns

Insider Turner William D.

Role Chief Regulatory Officer

Sold 10,000 shs ($501K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	10,000	$0.00	--
Exercise	Class A Common Stock	10,000	$15.53	$155K
Sale	Class A Common Stock	10,000	$50.0767	$501K

Holdings After Transaction: Stock Option (right to buy) — 245,000 shares (Direct); Class A Common Stock — 32,500 shares (Direct)

Footnotes (1)

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $50.00 to $50.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/4 of the shares subject to the option vested on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

12/17/2025 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turner William D.

(Last)

(First)

(Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE

94005

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	12/15/2025		M		10,000	A	$15.53	32,500	D
Class A Common Stock	12/15/2025		S⁽¹⁾		10,000	D	$50.0767⁽²⁾	22,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$15.53	12/15/2025		M			10,000	⁽³⁾	01/04/2034	Class A Common Stock	10,000	$0	245,000	D

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025.

2. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $50.00 to $50.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. 1/4 of the shares subject to the option vested on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date.

	/s/ Joseph R. Young, Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Vera Therapeutics (VERA) disclose?

Vera Therapeutics disclosed that its Chief Regulatory Officer exercised a stock option for 10,000 shares of Class A common stock at $15.53 per share and sold 10,000 shares on December 15, 2025.

At what prices did the Vera Therapeutics (VERA) officer buy and sell shares?

The officer acquired shares through an option exercise at $15.53 per share and sold 10,000 shares at a weighted average price of $50.0767 per share, with individual sale prices ranging from $50.00 to $50.11.

How many Vera Therapeutics (VERA) shares does the insider own after the transaction?

After the reported transactions, the officer directly owned 22,500 shares of Vera Therapeutics Class A common stock and held 245,000 stock options directly.

What type of derivative security did the Vera Therapeutics (VERA) insider exercise?

The insider exercised a stock option (right to buy) for 10,000 underlying shares of Class A common stock at an exercise price of $15.53 per share, with an option expiration date of January 4, 2034.

What is the vesting schedule for the Vera Therapeutics (VERA) stock option mentioned?

According to the disclosure, 1/4 of the shares subject to the option vested on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to the officer’s continuous service.